Capmatinib is a kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping. Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair.
- Mechanism
- Curator reviewed · 3 references
Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of MET exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity.
Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.
- Primary indication
- In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected...Curator reviewed · 2 structured indications
- Formula / weight
- C23H17FN6O · 412.428 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2020 · European Union, 2022
- Code names
- INC-280 · INCB-28060 · INCB-28060 FREE BASE
- Brand names
Resolves to
LIOLIMKSCNQPLV-UHFFFAOYSA-NSMILESCNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Capmatinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account